Navigation Links
Amgen Scholars Discover Their Potential During Summer Science Research Program and National Symposium
Date:7/20/2009

being selected for premier fellowships including Rhodes Scholarships."

Presentations during the symposium included talks on the drug discovery and development process and discussion of the many career options in academia and industry for scientists with a doctorate. Amgen Scholars also had the opportunity to network with academic and industry scientists and their peers.

"The Amgen Scholars Program gave me a realistic sense of what being a scientist is," said Janelle Ruiz, 2008 Amgen Scholar from Loyola Marymount University in Los Angeles who participated in the program at the University of Washington. "I discovered that a career in science is something that I should seriously consider."

In the U.S., Amgen Foundation's 10 host universities for the Amgen Scholars Program are California Institute of Technology; Columbia University/Barnard College; Howard University; MIT; Stanford University; University of California, Berkeley; UCLA; University of California, San Diego; University of California, San Francisco; and University of Washington.

MIT, which has long been at the forefront of undergraduate research programming, serves as the U.S. program office and plays a leading role in the coordination, technical oversight and student outreach for the program.

Each Amgen Scholars institution is in charge of selecting approximately 25 participants from both its own student body, as well as from other accredited four-year colleges and universities in the United States (U.S.), Puerto Rico and other U.S. territories. While each program site has its own application process, all require an official transcript with a cumulative GPA of 3.2 or above, a letter of recommendation and a personal statement or essay.

Financial support for students is a critical component of the program, which seeks to ensure that eligible students, regardless of their finan
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. Amgen Announces KRAS Safety Update to U.S. Prescribing Information for Vectibix(R) (Panitumumab)
2. Amgen Appoints Rebecca M. Henderson to the Companys Board of Directors
3. 34 Outstanding Teachers and Schools Receive $10,000 Amgen Award for Science Teaching Excellence
4. AUDIO from Medialink and Amgen: Experts Agree Infection in Cancer Patients Impacts Treatment Success
5. Amgen to Present at the Goldman Sachs Global Healthcare Conference
6. Loyola fellow receives Amgen grant to study treatments for older leukemia patients
7. Amgens Denosumab and Eli Lillys Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018
8. Amgen Highlights Data to Be Presented at ASCO
9. Amgen to Present at the Deutsche Bank 34th Annual Healthcare Conference
10. Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
11. Amgens First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... Omaha, Nebraska is a city of diversity, economic ... of the lowest unemployment rates in the country. Forbes Magazine ... for Business and Careers and it consistently scores high on ... located in the nation and is a strong business leader ... of Editions TV are pleased to announce air ...
(Date:5/19/2013)... Chicago, IL (PRWEB) May 19, 2013 In ... Surge, LLC, E-dentist.com has announced the launch of an SEO ... help dentists get high rankings in Google. , http://www.e-dentists.com/ ... do not pay for the service until they see results. ... sites. The lead generation websites run by JD Media Surge, ...
(Date:5/19/2013)... The muscles in the human body ... one of the biggest and most significant nervous systems ... peripheral system comprises of peripheral nerves that reside outside ... ensure that the limbs and hands, as well as ... get damaged due to trauma or physical injury, their ...
(Date:5/19/2013)... California (PRWEB) May 19, 2013 Grinding ... than just losing sleep, or annoying your spouse. At ... report by CNY Central (“Snoring and Teeth Grinding Could ... type of teeth grinding can be hard to prevent. ... million Americans, and one of its symptoms is a ...
(Date:5/19/2013)... 6Webs.com is the leader in reviews ... are considering an alarm system can do a comparison ... security system providers online at 6Webs.com. Just recently finishing ... home security system companies, 6Webs.com currently is announcing ... home security companies before ranking the home security system ...
Breaking Medicine News(10 mins):Health News:Editions TV Announces May Air Dates for Omaha, Nebraska 2Health News:Effective New Dental SEO Solution Launched by E-dentists.com in Partnership with JD Media Surge, LLC 2Health News:Ultimate Neuropathy Support System Launched by Neuracel - Reaching New Heights in Herbal Medication for Peripheral Neuropathy 2Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 2Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 3Health News:Top Rated DIY Home Security System Companies Published by 6Webs.com 2
... at Weill Cornell Medical College could prove a potent weapon ... called SS31, is able to cross the blood-brain barrier and ... damage. ,"In our experiments, we found that exposing ... a much smaller area of brain tissue being affected," says ...
... (WHO) has approved four new drugs manufactured by the Macleods ... one of the four would be used against some strains ... of these four medicines will reinforce efforts to scale up ... in a statement. ,The medicines are the first ...
... out that organically grown kiwifruit has more health benefits ... This study is reported in the SCI’s magazine Chemistry ... in January that consuming organic fruits was just a ... by Drs. Maria Amodio and Adel Kader, showed that ...
... up 21 community medical centres in 20 provinces. This is ... run by the state, many of which are overflowing with ... is also intended to bring improvements to medical services in ... has said that 13 centres will be built in the ...
... independent survey which was conducted in all mental health ... continue to remain in mixed wards//. This is much ... in 99% of hospitals. ,The healthcare commission ... sleeping accommodation or bathrooms with the opposite sex. This ...
... fatty acids docosahexaenoic acid (DHA) successfully reduced diastolic blood ... up previous results with higher doses. // ,"A ... likely to be of clinical significance with regard to ... lead author Hannah Theobald from King's College London. ...
Cached Medicine News:Health News:Antioxidant Molecule Could Help Minimize Stroke-Linked Brain Damage 2Health News:Indian Pharma Authorized to Market New Anti-TB Drugs 2Health News:organic kiwifruits promote health 2Health News:Hospital Projects to Take the Weight Off Overcrowded Ones 2Health News:Low-dose Omega-3 Linked to Lower Blood Pressure 2
(Date:5/17/2013)...  Sanofi (EURONEXT: SAN and NYSE: SNY ) ... , examining the selective JAK2 inhibitor SAR302503 for ... groups. The primary endpoint assessed the proportion of patients ... reported in previous trials, the most common adverse events ... be presented at an upcoming medical congress. ...
(Date:5/16/2013)... ZURICH , May 17, 2013 ... Research (A*STAR) and Switzerland,s Cytos Biotechnology ... dosed in a Phase 1 clinical trial with their H1N1 ... particle (VLP) technology. In this first Phase 1 clinical trial, ... its potential to protect against H1N1 influenza infection will be ...
(Date:5/16/2013)... N.C. , May 16, 2013  Today, the ... North Carolina House of Representatives recently approved ... for chemotherapy from charging patients higher out-of-pocket fees for ... formularies, many of which have more severe side-effects. However, ... limit of $300, which will continue to be a ...
Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3
... III study will evaluate effects of otelixizumab, an investigational anti-CD3 ... ... secretion, CAMBRIDGE, Mass., April 9, 2008 ... development of novel,therapies for immune-mediated diseases, today announced that it is,proceeding ...
... Calif., April 9, 2008 ,Poniard Pharmaceuticals, Inc. (Nasdaq: ... today announced that data from a Phase 2 ... patients with small,cell lung cancer (SCLC) will be ... Lung Cancer Conference in Geneva, Switzerland. The presentation ...
Cached Medicine Technology:Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting 2Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting 3Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting 4Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference 2Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: